Business Description
bioXXmed AG
ISIN : DE000A4BGGE4
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.99 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 0.59 | |||||
Beneish M-Score | 0.38 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -37.7 | |||||
3-Year EBITDA Growth Rate | 21.3 | |||||
3-Year EPS without NRI Growth Rate | 22.4 | |||||
3-Year FCF Growth Rate | 10.7 | |||||
3-Year Book Growth Rate | -4.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 49.23 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 23.54 | |||||
Quick Ratio | 23.54 | |||||
Cash Ratio | 21.64 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -11.6 | |||||
Shareholder Yield % | 69197.61 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -3425 | |||||
Net Margin % | -3305 | |||||
FCF Margin % | 329050 | |||||
ROE % | -3.08 | |||||
ROA % | -3.04 | |||||
ROIC % | -3.53 | |||||
3-Year ROIIC % | 8.92 | |||||
ROC (Joel Greenblatt) % | -4219.57 | |||||
ROCE % | -2.98 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 31 | |||||
PB Ratio | 0.03 | |||||
Price-to-Tangible-Book | 0.03 | |||||
Price-to-Free-Cash-Flow | 0.01 | |||||
Price-to-Operating-Cash-Flow | 0.01 | |||||
EV-to-EBIT | 1.92 | |||||
EV-to-EBITDA | 1.96 | |||||
EV-to-Revenue | -62.25 | |||||
EV-to-FCF | -0.02 | |||||
Price-to-Projected-FCF | 0.13 | |||||
Price-to-Net-Current-Asset-Value | 0.66 | |||||
Price-to-Net-Cash | 0.73 | |||||
Earnings Yield (Greenblatt) % | 52.11 | |||||
FCF Yield % | 11060.5 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
bioXXmed AG Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.02 | ||
EPS (TTM) (€) | -1.144 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0 | ||
20-Day SMA (€) | 159.5 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 159.5 - 159.5 | ||
Shares Outstanding (Mil) | 0.58 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
bioXXmed AG Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
bioXXmed AG Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
bioXXmed AG Frequently Asked Questions
What is bioXXmed AG(CHIX:T5O0d)'s stock price today?
When is next earnings date of bioXXmed AG(CHIX:T5O0d)?
Does bioXXmed AG(CHIX:T5O0d) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |